Humanigen

Recent News

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host DiseasePlanned interim assessment expected in 2024 following treatment of first 20 participantsShort Hills, New Jersey--(Newsfile Corp. - August 7, 2023) - Humanigen, Inc. (OTC Pink: HGEN), a clinical-stage biopharmaceutical company, today announced successful dosing of the first participant in the RATinG trial of lenzilumab for the early treatment of...
2023-08-07 8:01 AM EDT
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durableCMML is a rare, aggressive cancer; approximately 20% of patients survive three years...
2023-06-09 12:05 PM EDT
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented...
2023-04-14 12:05 PM EDT
Humanigen Reports Third Quarter 2022 Financial Results
Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood...
2022-11-14 4:01 PM EST
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will...
2022-11-10 8:02 AM EST
Humanigen Announces Retention of SC&H Capital as Financial Advisor
Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options. SC&H is an investment banking and advisory firm providing merger and acquisition (M&A), financial restructuring and related business advisory solutions to emerging and growing companies. Cameron Durrant, CEO Humanigen,...
2022-10-31 8:01 AM EDT
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML
Short Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - September 12, 2022) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, ("Humanigen") and the South Australian Health and Medical Research Institute ("SAHMRI") today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia ("PREACH-M") study of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a rare blood cancer, in patients with NRAS, KRAS, and CBL genetic mutations. The PREACH-M study will expand from the first two sites...
2022-09-12 6:55 AM EDT
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C. Wainwright 24th Annual Global Investment ConferencePresentation date: September 12, 2022Presentation time: 4:00 ETLocation: New York City, New YorkWebcast link:
2022-09-07 6:55 AM EDT
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a rare blood cancer, for which the PREACH-M study is already underway. Humanigen will also advance its plan...
2022-07-26 7:30 AM EDT
Humanigen Inc. Added to Russell 3000(R) Index
Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm', today announced that Humanigen has been added to the Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution.The event represents the ongoing accomplishments of Humanigen during a transformational year in developing lenzilumab for the treatment of newly hospitalized patients with COVID-19, and its intentions to continue to develop...
2021-06-28 11:46 AM EDT

Humanigen

Recent News

Get News by Email

Stock Quote

RSS Feeds

Tell Us Your Story

Cookie Settings

Get News by Email

Stock Quote

RSS Feeds

Tell Us Your Story